health-policy5.05 min read
CDC widens Ebola travel ban to include green-card holders who visited outbreak countries
3 days ago•Source: Politico
Health Policy News
The latest health policy stories, summarized by AI
Featured Health Policy Stories
View original source
11.57 min•5 days ago
Two Viruses Test America's Public Health Trust
Public health experts say Ebola and hantavirus pose no immediate threat to most Americans, but the outbreaks reveal a growing trust deficit and political polarization that could hamper responses to current crises and future pandemics.
More Top Stories
2
Texas Children’s Hospital Ordered to Open Detransition Clinic Under $10M Settlement
The Texas Tribune•11 days ago
3
California launches first US program giving free diapers to every newborn
The Guardian•17 days ago
More Health Policy Stories
FDA Gears Up Real-Time Trials Fueled by AI to Accelerate Drug Development
The FDA will speed drug development by reviewing real-time trial data from AstraZeneca and Amgen and is seeking public input on a pilot using AI to improve safety monitoring, dosing, and recruitment. The efforts include AZ’s Phase 2 lymphoma trial at MD Anderson and UPenn, and Amgen’s Phase 1b small cell lung cancer study, all supported by Paradigm Health’s real-time data platform.
Policy-Driven Hospital Consolidation Fuels Price Inflation, Report Warns
A policy-focused paper argues U.S. hospitals have become expensive largely because government policies reward consolidation and shield providers from competition—via CON laws, physician-owned hospital barriers, subsidies, and complex payment schemes—leading to prices rising faster than inflation even as outpatient care grows. Hospitals remain profitable, supported by Medicare/Medicaid and investment income, while price transparency is limited and costs are driven up by subsidies and consolidation. The report calls for site-neutral Medicare/Medicaid payments, tighter subsidy oversight, repeal of anticompetitive rules, targeted charity-care standards, and reform of hospital subsidies to reward efficiency and true need, aiming to restore competition and reduce costs for patients and taxpayers.
RAPID Pathway Aims to Fast-Track Medicare Coverage for Breakthrough Devices
CMS and FDA unveiled the RAPID coverage pathway to align FDA market authorization with Medicare national coverage decisions for eligible Breakthrough Devices (Class II and III). The program enables early, coordinated engagement with manufacturers, uses the FDA's market authorization to trigger a proposed NCD the same day, includes a 30‑day public comment period, and aims for coverage as soon as two months after FDA approval. The Transitional Coverage for Emerging Technologies (TCET) pathway will be paused to focus on RAPID, and a procedural notice will be published in the Federal Register for public input.
Kennedy seeks FDA reconsideration of 12 unproven peptides amid safety concerns
The FDA announced July 2026 and February 2027 advisory meetings to consider restoring access to 12 unproven peptides previously removed from a compounding-drug list due to safety risks, despite no new supporting safety or efficacy data. RFK Jr. has championed these peptides, claiming the meetings will “restore science,” while critics warn the Pharmacy Compounding Advisory Committee is under-staffed and at risk of being populated by allies, potentially circumventing standard drug-approval scrutiny. The seven peptides to be reviewed in July are BPC-157, KPV, TB-500, MOTs-C, Emideltide (DSIP), Semax, and Epitalon; the five scheduled for February 2027 are Cathelicidin LL-37, GHK-Cu, Dihexa-acetate, Melanotan II, and Mechano Growth Factor PEG-MGF, all of which lack proven uses.
FDA Urges 2,200 Sponsors to Publicly Disclose Trial Results
The FDA reminded more than 2,200 sponsors and researchers to submit mandatory clinical trial results to ClinicalTrials.gov, flagging risks from publication bias and incomplete public records. An internal review found about 29.6% of studies likely required to report have no results, and the agency issued voluntary compliance messages on March 30, 2026, with potential for noncompliance notices to ensure results are released for patient safety and informed clinical decisions.
States rely on consultants to enforce Trump-era Medicaid work rules
States are paying Deloitte, Accenture, Optum and other contractors millions to update Medicaid and SNAP eligibility systems to implement Trump’s work requirements, a move likely to drive up upfront costs while analysts project about 7.5 million fewer people could be uninsured by 2034 and roughly 2.4 million losing food assistance; Wisconsin, Iowa, Kentucky, Illinois and Vermont are among states lining up multi-million-dollar contracts as the federal government foots most of the bill.
Kennedy eyes FDA action to widen peptide access and spur a booming market
Health Secretary Kennedy Jr. signals that the FDA will broaden access to peptide therapies—a fast-growing, largely unregulated market—by taking action that could loosen rules for domestic compounding. Supporters say it will improve patient access, while critics warn of safety risks due to limited long-term data and a thriving gray/black market for unproven products. The move comes amid industry litigation, lobbying by compounding pharmacies, and high commercial interest in peptide-based treatments like GLP-1 therapies.
ACIP at Crossroads: Evidence vs. Politics in COVID Vaccine Policy
An Op-Ed argues that the reconstituted ACIP is relitigating COVID vaccine safety using an unvalidated PACVS framework, proposing unvalidated diagnostics and dubious prevalence, while ignoring robust VSD surveillance showing no excess mortality post-vaccination; internal dissent among work-group members and a court ruling suggesting the process violated the Administrative Procedure Act highlight concerns that policy is being guided by conclusions rather than evidence. The piece warns that replacing GRADE with a weaker evidentiary standard would undermine vaccine policy across all vaccines, and notes the March meeting was postponed, set against a public health backdrop of measles outbreaks.
FDA drafts framework to validate human-centric NAMs, trimming animal testing in drug development
The FDA issued a draft guidance to help drug developers validate new approach methodologies (NAMs) as replacements for animal testing in drug development, outlining four core validation principles—context of use, human biological relevance, technical characterization, and fit-for-purpose—and encouraging early consultation with FDA review divisions. NAMs encompass advanced in vitro systems, organoids and organ-on-chip models, in silico methods, and even phylogenetically lower organisms like zebrafish. The goal is to rely on human-relevant data to improve safety predictions and accelerate access to safer therapies, building on previous efforts to reduce animal testing and update related guidance on pyrogen/endotoxin testing.
Urgent Push for a National Covid Vaccine Injury Tracking Network
A confidential federal report prepared for the CDC’s ACIP urges sweeping changes to how Covid vaccine injuries are tracked and treated, proposing a dedicated vaccine-injury diagnostic category, updated diagnostic guidelines, and a network of research centers to study long-term harms from vaccines and the illness, signaling urgent policy action.